EUVIMEDEUVIMED entdecken
FallberichtOpen Access

BRAF–MEK inhibition in a giant BRAF-mutant Rathke cleft cyst: Diagnostic challenges and clinical implications for BRAF testing

Bertrand Baussart iD, Delphine Leclercq, Carine Courtillot, Florence Coulet, Suzanne Tran, Ahmed Idbaih iD, Chiara Villa iD

Neuro-Oncology Practice · 01.08.2026 · 13 (4) · 823-827

DOI: 10.1093/nop/npag035 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Neuro-Oncology Practice, online erschienen am 17.04.2026. Verfasst von Bertrand Baussart und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Lariboisière University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rathke cleft cysts are benign sellar lesions with a substantial risk of postoperative recurrence. In contrast to papillary craniopharyngiomas, oncogenic BRAF mutations are exceptionally reported in Rathke cleft cysts (RCCs), and the therapeutic relevance of targeted inhibition remains unknown. Case summary A 51-y-old man presented with a giant cystic suprasellar lesion involving the optochiasmatic and subfrontal regions. Following incomplete surgical resection, histopathological analysis confirmed the diagnosis of Rathke’s cleft cyst. Molecular profiling identified a somatic BRAF p. V600E mutation present in a subclonal population. Rapid recurrence occurred 3 months postoperatively. Combined BRAF/MEK inhibition with dabrafenib and trametinib was initiated, leading to a marked reduction in cyst volume on serial MRI, further enhanced after dose escalation. Treatment was well tolerated, with complete symptom resolution and no endocrine impairment.

Conclusion

This report describes the first adult BRAF-mutant RCC responding to BRAF/MEK-targeted therapy, supporting molecular profiling to guide personalized management in recurrent or high-risk RCCs.

Schlagwörter

Stichwörter der Autor:innen

BRAF mutationBRAF testingBRAF/MEK inhibitorsRathke cleft cysttargeted therapy

Autor:innen und Institutionen

  • Department of Neurosurgery, Lariboisière University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
  • CNRS, INSERM, Institut Cochin, Université Paris Cité, Paris, France.
  • Department of Functional and Diagnostic Neuroradiology, AP-HP, Pitié-Salpêtrière Hospital, Paris, France.
  • Department of Endocrinology and Reproductive Medicine, Centre de Référence des Maladies Endocriniennes Rares de la Croissance et du Développement, CRMERC, Endo-ERN, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne University…
  • Department of Medical Genetics, Sorbonne Université, Groupe Hospitalier Pitié-Salpêtrière, APHP, Paris, France.
  • Department of Pathology, Assistance Publique-Hôpitaux de Paris, Lariboisière University Hospital, Paris, France.

ORCID-Profile: Bertrand Baussart, Ahmed Idbaih, Chiara Villa

Zitieren

APA

Baussart, B., Leclercq, D., Courtillot, C., Coulet, F., Tran, S., Idbaih, A., & Villa, C. (2026). BRAF–MEK inhibition in a giant BRAF-mutant Rathke cleft cyst: Diagnostic challenges and clinical implications for BRAF testing. Neuro-Oncology Practice, 13(4), 823-827. https://doi.org/10.1093/nop/npag035

Vancouver

Baussart B, Leclercq D, Courtillot C, Coulet F, Tran S, Idbaih A, et al. BRAF–MEK inhibition in a giant BRAF-mutant Rathke cleft cyst: Diagnostic challenges and clinical implications for BRAF testing. Neuro-Oncology Practice. 2026;13(4):823-827. doi:10.1093/nop/npag035

BibTeX
@article{Baussart2026,
  author = {Baussart, Bertrand and Leclercq, Delphine and Courtillot, Carine and Coulet, Florence and Tran, Suzanne and Idbaih, Ahmed and Villa, Chiara},
  title = {BRAF–MEK inhibition in a giant BRAF-mutant Rathke cleft cyst: Diagnostic challenges and clinical implications for BRAF testing},
  journal = {Neuro-Oncology Practice},
  year = {2026},
  volume = {13},
  number = {4},
  pages = {823--827},
  doi = {10.1093/nop/npag035}
}
Kostenlos starten →